CDK9 and neoplasm: Furthermore, PRMT6 and cyclin-dependent kinase 9 (CDK9) have been reported to co-regulate the expression and activation of YTH N6-methyladenosine RNA binding protein 2 (YTHDF) by promoting degradation of adenomatous polyposis coli (APC) and glycogen synthase kinase 3β (GSK3β), negative regulators of the Wnt/β-catenin pathway, thereby exerting oncogenic effects in vitro and tumor models [197].